Pdt Partners, LLC Allakos Inc. Transaction History

Pdt Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.02 - $6.12 $808,164 - $1.64 Million	-267,604 Reduced 70.68%	111,022 $679,000
Q2 2022 Aug 15, 2022	SELL	$2.6 - $6.14 $733,072 - $1.73 Million	-281,951 Reduced 42.68%	378,626 $1.19 Million
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $2.87 Million - $5.54 Million	564,531 Added 587.77%	660,577 $3.77 Million
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $821,193 - $10.7 Million	96,046 New	96,046 $940,000
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $305,354 - $440,615	-3,990 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $340,626 - $455,259	3,990 New	3,990 $341,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $91.5M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.